Article summary
FDA laid out how the first federally funded ibogaine trials could be run, with inpatient cardiac monitoring and a 10 mg/kg starting dose ceiling. Compass Pathways executives discussed pricing as the COMP360 NDA nears completion, and state cannabis regulators say DEA still hasnβt answered their rescheduling questions.
Continue to the original publication for the complete article.